CS214312B1 - Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene - Google Patents

Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene Download PDF

Info

Publication number
CS214312B1
CS214312B1 CS739680A CS739680A CS214312B1 CS 214312 B1 CS214312 B1 CS 214312B1 CS 739680 A CS739680 A CS 739680A CS 739680 A CS739680 A CS 739680A CS 214312 B1 CS214312 B1 CS 214312B1
Authority
CS
Czechoslovakia
Prior art keywords
trans
isomer
formula
cyclohexene
phenyl
Prior art date
Application number
CS739680A
Other languages
Czech (cs)
Slovak (sk)
Inventor
Ladislav David
Alfonz Rybar
Emil Zlatinsky
Milan Breza
Anton Pekar
Augustin Martvon
Original Assignee
Ladislav David
Alfonz Rybar
Emil Zlatinsky
Milan Breza
Anton Pekar
Augustin Martvon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ladislav David, Alfonz Rybar, Emil Zlatinsky, Milan Breza, Anton Pekar, Augustin Martvon filed Critical Ladislav David
Priority to CS739680A priority Critical patent/CS214312B1/en
Publication of CS214312B1 publication Critical patent/CS214312B1/en

Links

Description

Vynález sa týká spSsobu přípravy 3-trans-dimetyl· amine/-4 -fenyl-4-trans-karbetoxy-l-cyklohexénu vzorce IThe present invention relates to a process for the preparation of 3-trans-dimethyl-amino / -4-phenyl-4-trans-carbethoxy-1-cyclohexene of the formula I

ktorý sa používá v medicíně ako analgetikum.which is used in medicine as an analgesic.

Doposial* sa táto zlúčenina připravovala izoláciou zo zmesi trans-izoméru vzorca I a cis-izoméru, t.j. 3-eis-dimetylamino-4-fenyl-4cis-karbetoxy-l-cyklohexénu vzorca IITo date, this compound has been prepared by isolation from a mixture of the trans-isomer of Formula I and the cis-isomer, i. 3-Eis-dimethylamino-4-phenyl-4-cis-carbetoxy-1-cyclohexene of formula II

CHCH

CHCH

3\.3 \.

214 312 /11/214 312/10 /

2i4 312 frakčnou kryštalizáciou ich hydrochloridov /DOS 1 923 619/, pomocou komplexu cis-izoméru s chloridom zinočnatým /DOS 1 923 620 a Nem.pat. 1 618 476/, alebo pomooou adičnej soli transizoméru I s kyselinou naftalén-1,5-disulfónovou /Nem.pat. 1 768 704 a DOS 2 134 821/.2,414,312 by fractional crystallization of their hydrochlorides (DOS 1,923,619), using the cis-isomer complex with zinc chloride (DOS 1,923,620 and Nem.pat. No. 1,618,476], or by using a naphthalene-1,5-disulfonic acid addition salt of transomer I (Nem. Pat. No. 1,768,704 and DOS 2,134,821 /.

Podstatou tohto vynálezu je příprava čistého trans-izoméru vzorca I, izoláciou zo· zmesi izomérov I a II pomocou aromatických sulfokarboxylových kyselin, s výhodou pomocou 5-sulfoizoftalovej kyseliny vzorca IIIThe present invention relates to the preparation of the pure trans-isomer of formula I by isolation from a mixture of isomers I and II with aromatic sulfocarboxylic acids, preferably with 5-sulfoisophthalic acid of formula III

s ktorou tvoří trans-izomér vzorca I v prostředí alifatického alkoholu s počtom uhlíkov 1 až 4, s výhodou v etanole, v prostředí alifatického ketonu s počtom uhlíkov 3 až 7, s výhodou v acetone, alebo ich zmesiach s vodou, estermi alifatických kyselin s počtom uhlíkov 2 až 6, s výhodou s etylacetátom, alebo s alifatickými alebo cyklickými étermi s počtom uhlíkov 3 až 8 a počtom kvslíkov 1 alebo 2, s výhodou s tetrahydrofuránom resp. dioxánom, izolovateťnd sol' vzorca IVwith which they form the trans-isomer of formula I in an aliphatic alcohol having a carbon number of 1 to 4, preferably in ethanol, an aliphatic ketone having a carbon number of 3 to 7, preferably acetone, or mixtures thereof with water, aliphatic acid esters with the number of carbons 2 to 6, preferably with ethyl acetate, or with aliphatic or cyclic ethers with a number of carbons of 3 to 8 and a number of yeasts of 1 or 2, preferably with tetrahydrofuran and 3-6, respectively. dioxane, an isolate salt of formula IV

Postup podťa vynálezu sa uskutočňuje tak, že sa k roztoku aromatickej sulfokarboxylovej kyseliny, s výhodou 5-sulfoizoftalovej kyseliny vzorca III, a alifatickém alkohole, s výhodou v etanole, alebo alifatickom ketone, s výhodou v acetone, přidá roztok izomérov I a II v alkohole, ketone, esteri alebo éteri, s výhodou v etanole, acetone, etiylacetáte alebo dioxáne resp. tetrahydrofuráne, pričom sa zmes samovolYie zahřeje na 30 až 50 °C. Po ochladení na -10 až +25 °C, s výhodou na 0 až +5 °C, vykrystalizuje sol1 aromatickej sulfokarboxylovej kyseliny s trans-izomérom vzorca IV, kým analogická sol* cis-izoméru II zostane v roztoku. Vyléčená sol1 sa odsaje, sespenduje vo vodě a přidáním silnej anorganickej alebo organické j bázy sa zo soli uvolní trans-izomér I. Tento sa vyextrahuje ineroným organickým rozpúšťadlom, najlepšie petroléterom, extrakt sa vysučí a rozpúštíadlo sa oddestiluje. Získá sa trans-izomér I vo výtažku 60 - 65 % s obsahom cis-izoméru II max. 1 % váh.The process according to the invention is carried out by adding a solution of the isomers I and II in an alcohol to a solution of an aromatic sulfocarboxylic acid, preferably 5-sulfoisophthalic acid of the formula III, and an aliphatic alcohol, preferably ethanol or an aliphatic ketone, preferably acetone. , ketone, ester or ether, preferably in ethanol, acetone, ethyl acetate or dioxane, respectively. tetrahydrofuran, the mixture being spontaneously heated to 30-50 ° C. After cooling to -10 to + 25 ° C, preferably to 0 to + 5 ° C, the aromatic sulfocarboxylic acid salt 1 of the trans-isomer of formula IV crystallizes while the analogous salt of the cis-isomer II remains in solution. The treated salt 1 is aspirated, suspended in water and the trans-isomer I is liberated from the salt by addition of a strong inorganic or organic base. This is extracted with an inorganic organic solvent, preferably petroleum ether, the extract is dried and the solvent is distilled off. The trans-isomer I is obtained in a yield of 60-65% with a content of cis-isomer II of max. 1% by weight

Výhodou tohto postupu oproti prv popísanému postupu s naftalén-1,5-disulfónovou kyselinou je použitie kyseliny čsl. proveniencie. Oproti daťším popísaným postupom je výhoda toh to postupu v zíkaní trans-izoméru I ve vačšej čistotě.The advantage of this process over the naphthalene-1,5-disulfonic acid process described above is the use of the acid no. provenance. Compared to the other processes described above, the advantage of this process is to obtain a higher purity of the trans-isomer I.

V dalšom je predmet vynálzú popísan^ v príkladoch provedenla bez toho že by sa na tieto obmedzoval.In the following, the subject of the invention described in the examples has been carried out without being limited thereto.

214 312214 312

Příklad 1 *Example 1 *

Do predom připraveného roztoku z 3,16 kg /11,97 mól/ kyseliny 5-sulfoizoftalovej monohjdrátu v 4·,4 1 etanolu sa za miešania a chladenia přidá roztok 4,56 kg bázy, obsahujúcej 60 % váh. trans-izoméru I /10 mól/ v 4,4 1 etylacetátu. Po ochladení roztoku a čiastočnom vypadnutí krvštálu sa přidá ešte 4,8 1 etylacetátu a zmes nechá miešať ešte 1,5 hod. Potom sa vypadnutá sol' odsaje, suspenduje sa v zmesi 41 etanolu a 6 1 etylacetátu a nechá sa mie šať pri izbovej teplote cca 20 min. Potom sa znova odsaje, přečištěný ktyštál sa suspenduje v 8 1 vody a báza sa. uvol'ní přidáním 50 %-ného roztoku hydroxydu sodného do pH 13. Vyléčená báza sa extrahuje petroléterom, petroléterový extrakt sa vysuší bezv. síranom sodným a petroléter sa oddestiluje. Získá sa 1,67 J&g. bázy s obsahom 95,15 % váh. 3-trans-dimetylamino-4-fenyl-4-trans-karbetoxy-l-cyklohexénu a menej ako 1 % váh. 3-cis-dimetylamino-4-fenyl-4-cis-karbetoxy-l-cyklohexénu vzorce II. Výtažek činí 61,1 %. Z matečných lúhov po oddesti lovaní rozpúšťadla sa vyššie spomínaný® postupom získá 1,16 kg bázy obsahujúcej 65 % váh. 3-cis-dimetylamino-4-fenyl-4-cis-karbetoxy-l-cyklohexénu a 15 % váh. 3-trans-dimety-amino-4 -fenyl-4-trans-karbetoxy-l-cyklohexénu vzorca I.To a previously prepared solution of 3.16 kg (11.97 mol) of 5-sulfoisophthalic acid monohydrate in 4 L of ethanol, a solution of 4.56 kg of a base containing 60% by weight is added under stirring and cooling. of the trans-isomer I (10 mol) in 4.4 L of ethyl acetate. After cooling the solution and partially precipitating the crystal, 4.8 L of ethyl acetate was added and the mixture was allowed to stir for 1.5 hours. The precipitated salt is then filtered off with suction, suspended in a mixture of 41 ethanol and 6 l of ethyl acetate and allowed to stir at room temperature for about 20 minutes. It is then aspirated again, the purified crystal is suspended in 8 l of water and the base is collected. The resulting base is extracted with petroleum ether, the petroleum ether extract is dried freely. sodium sulfate and the petroleum ether was distilled off. 1.67 J < g is obtained. base containing 95.15% by weight. 3-trans-dimethylamino-4-phenyl-4-trans-carbethoxy-1-cyclohexene and less than 1% by weight. 3-cis-dimethylamino-4-phenyl-4-cis-carbetoxy-1-cyclohexene of formula II. The yield was 61.1%. From the mother liquors after distilling off the solvent, 1.16 kg of a base containing 65% by weight are obtained as described above. % Of 3-cis-dimethylamino-4-phenyl-4-cis-carbethoxy-1-cyclohexene; 3-Trans-dimethylamino-4-phenyl-4-trans-carbethoxy-1-cyclohexene of formula I.

Příklad 2Example 2

K suspenzi! 28,8 g /0,11 mól/ kyseliny S-sulfoizoftalovej monohydrátu v 50 ml acetonu a 5 ml vody sa přidá pri teplote 30 až 40 °C za miešania roztok 40 g bázy obsahujúcej25 g trans-izoméru I /0,09 mól/ v 30 ml acetonu. Po ochladení vykryštaluzuje sol’ 3-trans-dimetylamino-4-fenyl-4-trans-karbetoxy-l-cyklohexénu-5-sulfoizoftalátu, ktorá sa čťalej spracuje ako v příklade 1. Získá sa 13,7 g bázy obsahujúcej 96 % váh. trans-izoméru I.To the suspension! 28.8 g (0.11 mol) of S-sulfoisophthalic acid monohydrate in 50 ml of acetone and 5 ml of water are added at 30 to 40 ° C with stirring a solution of 40 g of base containing 25 g of the trans-isomer I (0.09 mol). in 30 ml acetone. Upon cooling, the salt of 3-trans-dimethylamino-4-phenyl-4-trans-carbethoxy-1-cyclohexene-5-sulfoisophthalate crystallizes, which is further processed as in Example 1. 13.7 g of base are obtained, containing 96% by weight. trans-isomer I.

Příklad 3Example 3

K suspenzii 28,8 g /0,11 mól/ 5-sulfoizoftalovej kyseliny monohydrátu v 50 ml acetonu a 15 ml etanolu sa pri teplote 30 až 40 °C přidá za miešania roztok 40 g bázy obsahujúcej 25 g trans-izoméru I / 0,09 mól/ v 30 ml acetonu. Po ochladení vykryštalizuje sol1 3-trans-dimetylamino-4-fenyl-4-trans-karbetoxy-l-cyklohexénu 5-sulfoizoftalátu, ktorá sa po odsátí a přečištění spracuje ako v příklade 1. Získá sa 13,3 g bázy obsahujúcej 92 % váh.transizoméru I.To a suspension of 28.8 g (0.11 mol) of 5-sulfoisophthalic acid monohydrate in 50 ml of acetone and 15 ml of ethanol at a temperature of 30 to 40 ° C is added, with stirring, a solution of 40 g of base containing 25 g of the trans-isomer I / O. 09 mol / v 30 ml acetone. After cooling the crystallized salt 1 3-trans-dimethylamino-4-phenyl-4-carbethoxy-trans-l-cyclohexene 5-sulfoisophthalate to be the aspiration and purification processes as in Example 1 to give 13.3 g of a base consisting of 92% weight of transisomer I.

Příklad 4Example 4

K roztoku 18 g /0,068 mól/ 5-sulfoizoftalovej kyseliny monohydrátu v 60 ml dioxánu sa přidá roztok 20 g bázy obsahujúcej 12 g trans-izoméru I /0,044 mól/ rozpustenej v 20 ml dioxánu. Po naočkování za miešania a chladenia vykryštalizuje sol1 3-transTdimetylamino-4-fenyl-4-trans-karbetoxy-l-cyklohexénu 5-sulfoizoftalátu. Sol1 sa spracuje podobným postupom ako v příklade 1. Takto sa získá 6,2 g bázy obsahujúcéj 98 % váh. trans-izoméru I.To a solution of 18 g (0.068 mol) of 5-sulfoisophthalic acid monohydrate in 60 ml of dioxane is added a solution of 20 g of base containing 12 g of trans-isomer I (0.044 mol) dissolved in 20 ml of dioxane. After seeding with stirring and cooling crystallized salt of 3-1 transTdimetylamino-4-phenyl-4-carbethoxy-trans-l-cyclohexene 5-sulfoisophthalate. Sol 1 was treated in a similar manner to Example 1. 6.2 g of a base containing 98% by weight were obtained. trans-isomer I.

Claims (4)

1. Sposob přípravy 3-trans-dimetylamino-4-fenyl-4-trans-karbetoxy-l-cyklohexénu vzorce I1. A process for the preparation of 3-trans-dimethylamino-4-phenyl-4-trans-carbethoxy-1-cyclohexene of the formula I 214 312 /1/214 312/1 / CH ch3-x izoláciou zo zmesi trans-izoméru vzorca I a cis-izoméru vzorca II tvorbou adičnej soli trans-izoméru vzorca I s aromatickou sulfokarboxylovou kyselinou, vyznačuiúci sa tým, že ako aromatická sulfokarboxylová kyselina sa použije kyselina 5-sulfoizoftalová, v prostředí alifatického alkoholu s počtom uhlíkov 1 až 4, alifatického ketonu s počtom uhlíkov 3 až 7, alebo ich zmesiach s vodou, estermi alifatických kyselin s počtom uhlíkov 2 až 6, alebo s alifatickými resp. cyklickými étermi s počtom uhlíkov 3 až 8 a počtom kyslíkov 1 alebo 2.CH 3 -x by isolation from a mixture of the trans-isomer of formula I and the cis-isomer of formula II by formation of an addition salt of the trans-isomer of formula I with an aromatic sulfocarboxylic acid, characterized in that 5-sulfoisophthalic acid is used as aromatic sulfocarboxylic acid an aliphatic alcohol having a carbon number of 1 to 4, an aliphatic ketone having a carbon number of 3 to 7, or mixtures thereof with water, an ester of an aliphatic acid having a carbon number of 2 to 6, or an aliphatic resp. cyclic ethers having a carbon number of 3 to 8 and an oxygen number of 1 or 2. 2. Sposob přípravy zlúčeniny I podl’a bodu 1(vvznačujúci sa tým, že sa izolácia adičnej soli uskutočňuje v prostředí etanol - etvlacetát.2. A process for the preparation of compound I according to item 1 ( characterized in that the isolation of the addition salt is carried out in an ethanol-ethyl acetate medium). 3. Spásob prípřavy zlúčeniny I podl'a bodu 1( vyznačujúci sa tým, že sa izolácia adičnej soli uskutočňuje v prostředí aceton - voda.3. A process for the preparation of compound (I) according to claim 1 ( characterized in that the isolation of the addition salt is carried out in an acetone-water medium). 4. Sposob přípravy zlúčeniny ,1 podl’a bodu 1, vyznačujúci sa tým, že sa izolácia adičnej soli uskutočňuje v prostředí aceton - etanol.4. A process for the preparation of a compound of claim 1, wherein the isolation of the addition salt is carried out in an acetone-ethanol environment.
CS739680A 1980-11-03 1980-11-03 Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene CS214312B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CS739680A CS214312B1 (en) 1980-11-03 1980-11-03 Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS739680A CS214312B1 (en) 1980-11-03 1980-11-03 Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene

Publications (1)

Publication Number Publication Date
CS214312B1 true CS214312B1 (en) 1982-04-09

Family

ID=5423016

Family Applications (1)

Application Number Title Priority Date Filing Date
CS739680A CS214312B1 (en) 1980-11-03 1980-11-03 Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene

Country Status (1)

Country Link
CS (1) CS214312B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500119A1 (en) * 1998-04-28 2005-10-15 Russinsky Ltd TILIDINE METHANSULFONATE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL MASS HEREVON

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500119A1 (en) * 1998-04-28 2005-10-15 Russinsky Ltd TILIDINE METHANSULFONATE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL MASS HEREVON

Similar Documents

Publication Publication Date Title
RU2081121C1 (en) Method of synthesis of clavulanic acid or its pharmaceutically acceptable salts and ethers, clavulanic acid salt with amine
FI117438B (en) Process for producing optically enriched bupivacaine
SU1739845A3 (en) Method for synthesis of isoindolinone derivatives or their salts
CS204046B2 (en) Process for preparing /s/-alpha-cyano-3-phenoxybenzylalcohole
SU1195903A3 (en) Method of producing 1-phenyl-2-aminocarbonylindole compounds or their salts of acid connection
CH695216A5 (en) A method for manufacturing a non-hydrated salt of a piperidine derivative and a novel crystalline form thus obtainable of such a salt.
CS214312B1 (en) Method for the production of 3-trans-dimethylamino-4-phenyl-4-trans-carbetoxy-1-cyclohexene
CN110114333B (en) Improved synthesis of lysine acetylsalicylate glycine particles
JP2004511476A (en) Method for producing R (+) α-lipoic acid
SU1318168A3 (en) Method for producing substituted thiazolidinyl esters of phosphoric acid
JP3981520B2 (en) Method for separating organic compounds
US4579686A (en) Process for the preparation of easy-flowing (flowable) oxytetracyclin hydrochloride
US4495356A (en) 1,4-Dihydropyridine compound
CN112898346A (en) Water-soluble polycyclic compound, and pharmaceutical composition and application thereof
CH483397A (en) Process for the preparation of phenylalanine derivatives
US3367948A (en) Novel d-threo-1-phenyl-2-amino-propane-1, 3-diol-derivatives
JPS606958B2 (en) Antibiotic purification method
US4496577A (en) Imidazolidinone prostaglandins, compositions and use
DD240207A5 (en) PROCESS FOR PREPARING ASYMMETRIC HYDANTOINE
US4001216A (en) Aminoalkyl ethers of 2,2'- and 3,3'-dihydroxydesoxybenzoin
SU1133842A1 (en) Method of obtaining trans-1,4,5,6-tetrahydro-1-methyl-2(2-2-thienyl-vinyl)pyrimidine pamoat
US20240051984A1 (en) Method for preparing disodium 5'-guanylate heptahydrate crystal
FI77648C (en) FRUIT PROCESSING FOR CITRATES, MALATES, FUMARAT AND PAMOAT AV 2-DIETHYLAMINO-1-METHYLTHYL-CIS-1-HYDROXY (BICYCLOHEXYL) -2-CARBOXYL SAMT VID FOERFARANDENA ANVAENT
EP0437566A1 (en) Phenyl-glycine derivatives.
RU2088586C1 (en) Method of preparing clavulanic acid or its pharmaceutically acceptable salts or esters